Capricor Therapeutics has announced its deramiocel cell therapy continues to be safe and effective after three years for Duchenne muscular dystrophy (DMD). The Phase II (NCT03406780) three-year ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...

Linda Marbán, Ph.D., the Chief Executive Officer of Capricor, emphasized the significance of this milestone, highlighting the potentially transformative impact of deramiocel on individuals grappl ...

seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy, DMD, cardiomyopathy. The full submission of the rolling BLA was ...

“We believe that the strength of this application is that deramiocel has shown in multiple clinical trials attenuation of the cardiac implications of DMD. We look forward to working with the FDA ...

Cell therapy developer Capricor Therapeutics (NASDAQ:CAPR) announced Thursday the completion of the U.S. marketing application for its lead candidate, deramiocel, for patients with Duchenne ...

"We believe that the strength of this application is that deramiocel has shown in multiple clinical trials attenuation of the cardiac implications of DMD. We look forward to working with the FDA ...

Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application (BLA) to the FDA seeking full approval for deramiocel to ...